A clinical study of docetaxel with or without 5'DFUR as a second-line chemotherapy for advanced gastric cancer.
We conducted a clinical pilot study to evaluate the efficacy and safety of the combination of docetaxel and 5'DFUR as a second-line chemotherapy for gastric cancer. Twenty-four patients were divided into two groups by simple randomization: group A (60 mg/m2 of docetaxel, every 3 wk) and group B (regimen A + 600 mg/body of 5'DFUR). The response rate was 17% and 42% in group A and B, respectively (p < 0.05). The MST from the start of the first-line was 17 mo in group B. The major adverse event was leukopenia in both groups.
Maruta
Fukuto
F
Department of Surgery, Shinshu University School of Medicine, Japan. maruta@hsp.md.shinshu-u.ac.jp
Ishizone
Satoshi
S
Hiraguri
Manabu
M
Fujimori
Yoshiro
Y
Shimizu
Fumiaki
F
Kumeda
Shigeyoshi
S
Miyagawa
Shinichi
S
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000077143:Docetaxel; D005260:Female; D005467:Floxuridine / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011379:Prognosis; D013274:Stomach Neoplasms / Q000188:drug therapy*; D015996:Survival Rate; D043823:Taxoids / Q000008:administration & dosage
D043823:Taxoids; D005467:Floxuridine; D000077143:Docetaxel; C025034:doxifluridine